Oral RORy nuclear receptor antagonist

on-going Ph. II for psoriasis (QD dosing)

50k cmpd high-conc. frag. screen + scaff. hop

ACS Med. Chem. Lett., Jan. 5, 2021

Boehringer Ingelheim, Ridgefield, CT

Chemical structure of molecule BI-730357

The Boehringer RORĪ³ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORĪ³ modulators last…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: